A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50–200 mg m(−2)) orally for 5 consecu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Khan, O A, Ranson, M, Michael, M, Olver, I, Levitt, N C, Mortimer, P, Watson, A J, Margison, G P, Midgley, R, Middleton, M R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2008
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2391129/
https://ncbi.nlm.nih.gov/pubmed/18475294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604366
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller